Seeking Alpha

Steve Rosenman's  Instablog

Steve Rosenman
Send Message
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of... More
  • OMTH Proposed IPO Non-Starter 9 comments
    Mar 13, 2013 11:39 AM | about stocks: AMRN

    Omthera proposes IPO. Good luck with that, having similar efficacy as Lovaza but several years behind. Not as effective as Vascepa as treatment, and I would say not a candidate for FDA approval with any sort of protection (read: Generic Lovaza will make Epanova meaningless). With their current therapy, not a candidate for expanding indication.

    Stocks: AMRN
Back To Steve Rosenman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (9)
Track new comments
  • ItachiUchiha
    , contributor
    Comments (18) | Send Message
     
    Steve has the OB been delayed again?
    13 Mar 2013, 05:17 PM Reply Like
  • onecardchuck
    , contributor
    Comments (40) | Send Message
     
    Yes it has been delayed again.
    14 Mar 2013, 08:51 AM Reply Like
  • Deep.Blue
    , contributor
    Comments (131) | Send Message
     
    Most likely seeking IPO as they found no buyers for the company. Gauntlet for Omthera - get IPO proceeds, launch sales force, likely fail at Anchor indication given statistically significant increase in LDL, deal w/ Vascepa, Lovaza and Lovaza generics. Still the market is very big and they need only a small piece of it to not go to zero...
    14 Mar 2013, 10:32 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » They wont have anchor indication, just Marine.
    14 Mar 2013, 11:57 AM Reply Like
  • Scientist on Stocks
    , contributor
    Comments (182) | Send Message
     
    probably the only advantage they may have got over lovaza/vascepa is reduced dose size...but i don't think thats an alternative to to efficacy
    16 Mar 2013, 10:20 AM Reply Like
  • nader1022
    , contributor
    Comments (5) | Send Message
     
    Steve, is there any near term catalyst ?
    22 Mar 2013, 10:51 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » I outlined Amarin catalysts in my latest article. Please review that.
    22 Mar 2013, 04:29 PM Reply Like
  • voltnfan
    , contributor
    Comments (7) | Send Message
     
    Steve, I requested info from Amarin regarding whether the 30 day free supply is counted through IMS but as I have discovered they do not respond to shareholder inquiries. My question to you though is this.......The "free" scripts actually are paid scripts....since Amarin does pay for those 30 day "free" scripts how is it you consider them unpaid scripts?
    26 Mar 2013, 05:03 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » I answered this on another post and directly to you, so why do you keep asking?
    26 Mar 2013, 08:46 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.